On Tuesday, Lucid Diagnostics Inc (NASDAQ: LUCD) was 3.17% up from the session before settling in for the closing price of $1.26. A 52-week range for LUCD has been $0.68 – $1.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 119.69% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 34.18%. With a float of $41.07 million, this company’s outstanding shares have now reached $84.37 million.
In an organization with 72 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -87.22%, operating margin of -1506.27%, and the pretax margin is -3240.88%.
Lucid Diagnostics Inc (LUCD) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lucid Diagnostics Inc stocks. The insider ownership of Lucid Diagnostics Inc is 62.03%, while institutional ownership is 9.78%.
Lucid Diagnostics Inc (LUCD) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.27% during the next five years compared to -54.43% drop over the previous five years of trading.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
You can see what Lucid Diagnostics Inc (LUCD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.72. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 33.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Lucid Diagnostics Inc (LUCD)
Let’s dig in a bit further. During the last 5-days, its volume was 0.87 million. That was better than the volume of 0.86 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 86.48%. Additionally, its Average True Range was 0.09.
During the past 100 days, Lucid Diagnostics Inc’s (LUCD) raw stochastic average was set at 52.38%, which indicates a significant decrease from 88.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.54% in the past 14 days, which was lower than the 87.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3407, while its 200-day Moving Average is $1.0341. However, in the short run, Lucid Diagnostics Inc’s stock first resistance to watch stands at $1.3333. Second resistance stands at $1.3667. The third major resistance level sits at $1.4033. If the price goes on to break the first support level at $1.2633, it is likely to go to the next support level at $1.2267. The third support level lies at $1.1933 if the price breaches the second support level.
Lucid Diagnostics Inc (NASDAQ: LUCD) Key Stats
There are 108,189K outstanding shares of the company, which has a market capitalization of 140.65 million. As of now, sales total 4,350 K while income totals -45,530 K. Its latest quarter income was 830 K while its last quarter net income were -26,910 K.
